Subtotal Petrosectomy (STP)

Definition and Concept

1. Blind sac closure (BSC) of the external auditory canal (EAC) - the EAC skin is removed and the meatus is closed in two layers, permanently separating the canal from the outside world
2. Canal wall down mastoidectomy (CWDM) with complete removal of all middle ear epithelium and pathology
3. Exenteration of all mastoid, perisigmoid, perilabyrinthine, perifacial, and hypotympanic cells - with retention of the otic capsule, fallopian canal, and middle and posterior fossa plates
4. Obliteration of the surgical cavity with abdominal fat, plus Eustachian tube occlusion

Indications

Primary / Otological Indications

Cochlear Implantation (CI) Indications

• Chronic otitis media / cholesteatoma / osteoradionecrosis
• Existing radical cavity or prior canal wall down surgery
• Cochlear ossification / obliteration
• Inner ear malformations (especially IP-I and IP-III, which risk CSF gusher - STP with blind sac closure and ET obliteration hermetically seals the ear)
• Temporal bone fracture involving the otic capsule
• Unfavorable anatomical conditions
• Revision CI surgery in an infected field
• Skull base lesions where the cochlear nerve and cochlea are preserved

Skull Base Indications

• Jugular foramen tumors (paragangliomas, schwannomas): STP extends atticomastoidectomy to enable wider facial nerve transposition. According to Scott-Brown's Otorhinolaryngology: "In order to be able to mobilize the facial nerve more extensively, atticomastoidectomy should be extended to subtotal petrosectomy. This involves removal of the skin of the external auditory meatus along with the tympanic membrane, the malleus and incus, drilling away the posterior canal wall and extensive exenteration of pneumatic cells."
• Class B3 tympanomastoid paragangliomas (8.3% of Prasad's series)
• Petroclival lesions (chordomas, meningiomas, cholesterol granulomas) - as a component of extended skull base approaches
• Parotid neoplasms requiring mastoidectomy in a field at high risk for radionecrosis - STP with obliteration is used prophylactically

Surgical Technique

Positioning and Setup

• Supine with head rotated, facial nerve monitoring mandatory
• Retroauricular incision (C-shaped or extended postauricular), wider shaving than standard CI

Step 1 - Blind Sac Closure of EAC

• Circumferential incision at the bony-cartilaginous junction
• Complete removal of EAC skin (lateral and medial portions)
• Annulus, malleus, and incus removed
• Meatus closed with anterior pedicled musculoperiosteal flap in two watertight layers

Step 2 - Canal Wall Down Mastoidectomy

• Complete atticomastoidectomy with removal of the posterior canal wall
• All middle ear epithelium removed; tympanic membrane, ossicles, and any disease cleared

Step 3 - Cell Exenteration

• Exenteration of: mastoid cells, perisigmoid cells, perilabyrinthine cells, perifacial cells (around the fallopian canal), and hypotympanic bone/cells
• Structures preserved: otic capsule (cochlea and labyrinth), fallopian canal (with facial nerve intact), middle fossa dural plate, posterior fossa/sigmoid sinus plate
• Eustachian tube orifice is obliterated (with muscle plug, bone wax, or a combination)

Step 4 - Cavity Obliteration

• Surgical defect filled with abdominal fat (harvested from a separate incision)
• Fat obliteration eliminates all dead space, prevents fluid accumulation and infection

For CI: The Cochleostomy

• After obliteration setup, cochleostomy is performed through the round window or via a cochleostomy anterior-inferior to it
• Array inserted; lead exited to the implant bed through a separate bony channel
• Cavity then packed with fat around the electrode

For Skull Base Extension (jugular foramen)

• After STP, the facial nerve is mobilized from its full mastoidal and tympanic segments
• Rerouted anteriorly with the pivot at the second genu (limited) or first genu (maximum exposure)
• Sigmoid sinus/jugular bulb controlled with Surgicel packing or ligation
• IJV ligated high in the neck after extending the incision inferiorly

Key Anatomical Landmarks and Relations

• Otic capsule: preserved (distinguishes STP from total petrosectomy)
• Fallopian canal: skeletonized but preserved (the facial nerve remains in situ unless transposition is needed)
• Sigmoid sinus: skeletonized during cell exenteration
• Jugular bulb: dome exposed by diamond burr removal of overlying bone
• Eustachian tube: obliterated to prevent reflux of secretions into the cavity
• Internal carotid artery: petrous segment at risk in extensive procedures; must be identified and protected

Outcomes (Prasad et al., largest series - 460 cases)

• 64.6% of patients had undergone multiple prior surgeries before STP
• Complications rate: very low - recidivism and postauricular wound fistula were the most common at only 1.1% each
• CI outcomes after STP: comparable to standard CI; 80% of cases can be done as a single-stage procedure
• A 2023 Italian multicenter review (PMID 37698103) of 55 patients (mean follow-up 44 months) confirmed STP + CI is safe; cholesteatoma was the most common indication; single-stage surgery was the preferred strategy

Complications

• Recidivism of cholesteatoma (if epithelium removal incomplete before obliteration): most important long-term risk
• Postauricular wound fistula / fat necrosis: fat may liquefy, creating a fistulous tract
• Facial nerve injury: risk varies with degree of transposition required
• CSF leak: particularly with skull base extensions or in cases with pre-existing dural defects
• Device extrusion or infection (CI cases): dramatically reduced by STP compared to implanting into a diseased ear
• Postoperative meningitis: reduced by hermetic sealing

Comparison to Related Procedures

Summary

Bell's Palsy

Definition and Epidemiology

• Incidence: ~23-25 per 100,000 per year; roughly 1 in 60 persons in a lifetime
• Sex: affects men and women approximately equally
• Age: any age; peak incidence in the 15-45 year range
• Risk factors: pregnancy (especially third trimester and early postpartum, up to threefold increase cited), diabetes mellitus, hypertension, immunosuppression
• Recurrence: ~7-8% of cases; average interval ~10 years between episodes

Pathophysiology

1. Inflammatory edema of the facial nerve
2. Compression of the swollen nerve within the tight confines of the fallopian canal
3. Ischemia and demyelination - or in severe cases, axonal degeneration

Clinical Features

• Inability to close the eye (lagophthalmos) - risk of corneal exposure injury
• Loss of nasolabial fold, drooping of the corner of the mouth
• Inability to wrinkle the forehead (distinguishes LMN from UMN palsy)
• Inability to puff out cheeks, whistle, or show teeth on the affected side

• Pain behind the ear (mastoid region) - may precede paralysis by 1-2 days; occasionally intense and persistent
• Loss of taste on the anterior two-thirds of the tongue (chorda tympani involvement) - indicates the lesion is proximal to where the chorda tympani joins the main nerve
• Hyperacusis - paralysis of the stapedius muscle (nerve to stapedius branch) causes recruitment of loud sounds on the ipsilateral side
• Mild numbness or fullness in the face (some patients), though true sensory loss is uncommon
• Reduced lacrimation or salivation in some cases (greater superficial petrosal nerve involvement)

Grading

Differential Diagnosis

Investigations

1. Typical acute presentation
2. No risk factors pointing to another cause
3. No vesicular rash in the ear (which would suggest Ramsay Hunt)
4. Normal neurological exam apart from CN VII
5. Normal otoscopy and hearing

• MRI with gadolinium: Shows swelling and smooth linear enhancement of the geniculate ganglion and facial nerve segments within the temporal bone (genu, tympanic, mastoid segments). This is highly suggestive of Bell's palsy but is not pathognomonic - Lyme disease, sarcoidosis, and perineural malignant spread can look identical.
• Blood glucose / HbA1c (diabetes)
• ESR / CRP
• Lyme serology (in endemic areas)
• HIV serology
• ACE level + chest imaging (sarcoidosis)
• Lumbar puncture (if Guillain-Barré suspected - bilateral palsy, areflexia)

• Evidence of denervation on EMG after 10 days indicates axonal degeneration - predicts prolonged recovery (3+ months) and possible incomplete recovery
• Electroneurography (ENoG): >90% degeneration correlates with poor prognosis
• Early motor recovery within 5-7 days is the most favorable prognostic sign

MRI Appearance

Treatment

1. Corticosteroids (strongly recommended)

• Prednisone 60-80 mg/day for the first 5 days, then tapered over the next 5 days (Harrison's 22E)
• Alternative: prednisolone 40-60 mg/day for 7-10 days
• Mechanism: reduces nerve edema and pressure within the fallopian canal
• Benefit: modestly but significantly shortens recovery and improves functional outcome
• The 2023 Japanese clinical practice guidelines (PMID 39079445) strongly recommend systemic standard-dose corticosteroids; high-dose corticosteroids showed no significant advantage over standard-dose in a 2023 systematic review and meta-analysis (PMID 36706448)
• Children: recovery rate is ~90% regardless of treatment; steroid use is debated and not universally recommended

2. Antiviral agents (weakly recommended)

• Most large randomized trials, including the landmark Sullivan trial, found no added benefit of valacyclovir or acyclovir over corticosteroids alone
• Should be added if vesicular lesions are present in the EAC or palate (suggesting VZV/Ramsay Hunt), or in severe/complete palsy
• Regimens: valacyclovir 1000 mg/day for 5-7 days, or acyclovir 400 mg five times daily for 10 days
• One RCT (Hato et al.) suggested additive benefit of valacyclovir + prednisolone over prednisolone alone in complete palsy - hence weak recommendation persists in guidelines
• Oral vs. IV steroids: a 2024 meta-analysis (PMID 37940744) found no significant difference between oral and IV steroid administration

3. Eye care (mandatory)

• Artificial tears during the day (lubricating eye drops)
• Lubricating eye ointment at night
• Tape the upper eyelid shut during sleep to prevent corneal drying (lagophthalmic keratitis)
• In severe lagophthalmos: moisture chamber, temporary tarsorrhaphy, or gold weight implant in upper eyelid

4. Physical therapy

• Facial neuromuscular retraining, massage, mirror exercises
• A 2025 systematic review (PMID 39647183) supports physical therapy for idiopathic facial palsy, though evidence quality remains limited

5. Surgical decompression

• Not recommended as routine treatment - there is no good evidence of benefit, and it may cause harm
• The 2023 Japanese guidelines weakly recommend it only in selected severe cases
• Decompression of the meatal foramen (narrowest part of the fallopian canal, where the nerve is most compressed) has been proposed, but the evidence base remains weak

6. Botulinum toxin / reanimation surgery

• Botulinum toxin useful for synkinesis (aberrant reinnervation causing co-contraction) after recovery
• Surgical reanimation (nerve grafting, muscle transfer, static procedures) for permanent paralysis

Prognosis

• ~70% recover completely within 1-2 months; ~85% achieve near-normal function (Adams & Victor)
• ~80% recover within weeks to months (Harrison's)
• Incomplete paralysis in the first week = most favorable prognostic sign
• Early return of taste in week 1 = favorable sign
• Complete paralysis at onset + >90% degeneration on ENoG = poor prognosis
• Axonal degeneration (seen after 10 days on EMG) predicts 3+ month delay in recovery
• Recurrence rate: ~7-8% of cases

Bell's Palsy in Pregnancy

• Incidence is increased, particularly in the third trimester and first 2 weeks postpartum (up to threefold cited, though disputed)
• Managed similarly to non-pregnant patients; short-course prednisolone is generally considered safe after the first trimester
• Antivirals: use with caution; consult obstetric guidance

Key Teaching Points

• Always check the ear (otoscopy) and hearing before labelling a facial palsy as Bell's - abnormal findings point to an alternative diagnosis
• Check for vesicles in the EAC - if present, this is Ramsay Hunt (VZV), not Bell's, and requires antiviral therapy
• Forehead involvement confirms peripheral (LMN) palsy - if the forehead is spared, suspect a central (UMN) lesion
• Steroids within 72 hours = best outcomes; beyond 72 hours the benefit is unproven
• Protect the cornea - exposure keratitis is the most urgent complication

Coblation in ENT

The Technology - What is Coblation?

Mechanism of Action

• Monopolar electrocautery: >400°C
• Bipolar diathermy: ~400°C
• Laser: very high focal temperatures
• Harmonic scalpel: mechanical energy but generates ~80°C

ENT Applications

1. Tonsillectomy

• Multiple studies show coblation is comparable to electrocautery for postoperative pain, hemorrhage, and recovery - K.J. Lee's Essential Otolaryngology
• A Cochrane review of nine trials found no significant differences in pain or speed of recovery between coblation and other tonsillectomy techniques - Cummings Otolaryngology
• A 2023 systematic review and meta-analysis of 6 studies (1,824 adult patients) comparing coblation vs. bipolar diathermy found no significant differences in reactionary hemorrhage (OR 1.81, p=.51), delayed hemorrhage (OR 0.72, p=.20), or postoperative pain, though there was a general trend favoring coblation and a greater healing effect on tonsillar tissue. Coblation had a slightly longer operating time. (PMID 33719616)
• Post-tonsillectomy hemorrhage remains the most feared complication and rates with coblation are comparable to other techniques (~1-5%)

2. Adenoidectomy

• Less intraoperative blood loss
• More complete adenoid removal (particularly of residual lateral nasopharyngeal tissue)
• Allows precise tissue removal under vision, reducing the risk of damage to the Eustachian tube orifices and soft palate
• Cost limitation: the high unit cost of single-use wands restricts its use as a sole procedure for adenoidectomy alone; however, when tonsillectomy is being performed simultaneously using the same wand, the marginal cost of performing adenoidectomy is negligible

3. Inferior Turbinate Reduction

4. Tongue Base Reduction for OSA

5. Recurrent Respiratory Papillomatosis (RRP)

6. Soft Palate Surgery / Uvulopalatoplasty (for Snoring and OSA)

7. Other ENT Uses

• Head and neck tumor palliation: RF ablation for symptom control in unresectable tumors
• Microcystic lymphatic malformations: intralesional coblation ablation
• Nasal polyp debulking: adjunct to FESS
• Lingual tonsil reduction: in tongue base hypertrophy contributing to OSA

Coblation vs. Other Techniques: Summary Comparison

Advantages of Coblation

1. Low thermal tissue damage - no charring, minimal collateral injury
2. Simultaneous ablation and haemostasis in a single instrument
3. Mucosal preservation in submucosal applications (turbinates, tongue base, soft palate)
4. Reduced post-operative pain compared to monopolar diathermy (though evidence is mixed vs. bipolar)
5. Single-use wands eliminate cross-infection risk
6. Versatile - multiple wand designs for tonsil, larynx, turbinate, tongue base, adenoids
7. Can be used in office-based settings under local anaesthesia (turbinate reduction, tongue base)

Disadvantages / Limitations

1. High unit cost of single-use wands - limits use especially for isolated adenoidectomy
2. Longer operating time compared to electrocautery in some studies
3. Evidence for pain advantage is mixed - not consistently proven superior to bipolar diathermy in meta-analyses
4. Requires saline irrigation or gel at the tip for plasma generation - slightly more complex technique
5. Post-tonsillectomy haemorrhage rate not demonstrably lower than other standard techniques
6. Limited evidence for some applications (RRP, laryngeal use)

Key Points for Exams

• Coblation works via plasma-mediated molecular dissociation, not conventional heat transfer
• Operating temperature: 40-70°C (vs. ~400°C for conventional diathermy)
• Requires a conductive saline medium to generate the plasma field
• In tonsillectomy: comparable outcomes to other techniques; no definitive superiority for pain or haemorrhage
• In turbinate reduction: classified as mucosal preservation surgery - preferred over destructive techniques
• Tongue base coblation for OSA: ~45% reduction in RDI long-term
• Not to be confused with radiofrequency ablation (RFA) used in thyroid nodules/head-neck tumors - though the RF principle is shared, the mechanisms and applications differ